Why the study?
Do direct thrombin inhibitors improve outcomes compared to unfractionated heparin and indirect thrombin inhibitors in patients undergoing percutaneous coronary intervention?
Do direct thrombin inhibitors improve outcomes compared to unfractionated heparin and indirect thrombin inhibitors in patients undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
This review evaluates the pharmacological properties and clinical data for direct thrombin inhibitors as alternative anticoagulants during percutaneous coronary intervention.
Direct thrombin inhibitors (DTI) are emerging as alternative anticoagulants to unfractionated heparin and indirect thrombin inhibitors in patients undergoing percutaneous coronary intervention (PCI). We review the pharmacological properties of these newer antithrombotic agents and evaluate the clinical data demonstrating their use in patients undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Kokolis et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: